L-744832

L-744832 is a farnesyl transferase inhibitor. L-744832 effectively inhibits the farnesylation of H-Ras and N-Ras, but has little effect on K-Ras treatment. L-744832 not only directly targets the oncogenic pathway by inhibiting Ras farnesylation, but also enhances radiosensitivity by restoring TGF-β signaling through epigenetic reprogramming. L-744832 can induce cell cycle arrest and apoptosis. L-744832 can be used in combination therapy studies for Ras-driven tumors such as pancreatic cancer[1][2].

Product Specifications

CAS Number

[160141-09-3]

UNSPSC

12352200

Target

Apoptosis; Farnesyl Transferase; Ras; TGF-β Receptor

Related Pathways

Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Metabolic Enzyme/Protease; TGF-beta/Smad

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Smiles

O=C(OC(C)C)[C@@H](NC([C@@H](OC[C@@H](NC[C@@H](N)CS)[C@@H](C)CC)CC1=CC=CC=C1)=O)CCS(=O)(C)=O

Molecular Formula

C26H45N3O6S2

Molecular Weight

559.78

References & Citations

[1]Song SY, et al. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia. 2000 May-Jun;2 (3) :261-72. |[2]Alcock RA, et al. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2. Oncogene. 2002 Nov 7;21 (51) :7883-90.